Prognostic Value of CV Biomarkers, End Points in Cancer Screening Trials, USPSTF on Breast Cancer Screening, and more

JAMA Editor’s Summary

Prognostic Value of CV Biomarkers, End Points in Cancer Screening Trials, USPSTF on Breast Cancer Screening, and more

Editor’s Summary by Mary McGrae McDermott, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for the , issue.

June 11, 2024

Listen on your favorite player Take me to this show’s page

Newer →

Krill Oil for Knee Osteoarthritis, EHR Prompts to Improve Antibiotic Selection, FTC Action on Prescription Drugs, and more

← Older

Ponatinib vs Imatinib for Ph+ ALL, Cholesterol from Childhood to Adulthood and CVD Risk, Causal Inference, and more

Facebook Twitter Buffer LinkedIn WhatsApp

Prognostic Value of CV Biomarkers, End Points in Cancer Screening Trials, USPSTF on Breast Cancer Screening, and more

Editor’s Summary by Mary McGrae McDermott, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for the June 11, 2024, issue.

Listen on your favorite player

New to Podcasts? It's easy to get started!

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Join Our Newsletter

We gratefully acknowledge the many organizations that have generously supported our podcasts and platform.

Network Sponsors and Advertisers

Event and Media Partners

00:00

00:00